ESMO Asia 2016
The 2nd European Society for Medical Oncology (ESMO) Asia congress took place on 16–19 December 2016 at the Suntec Singapore Convention & Exhibition Centre, Singapore.
Boehringer Ingelheim hosted a satellite symposium entitled ‘NSCLC treatment updates: Connecting evidence to clinical practice’, which was held on Saturday 17 December 2016, 18:00–19:20. The meeting was chaired by Prof. Ross Soo and included presentations from Prof. Daniel Tan and Prof. Solange Peters.
In addition to the symposium, an oral presentation on the overall survival analysis from the LUX-Lung 7 trial and a poster describing the analysis of tumour and serum biomarkers in the LUX-Lung 8 trial were presented. See below for further details.
The full ESMO Asia 2016 programme can be found here.
NSCLC treatment updates: Connecting evidence to clinical practiceSaturday 17 December 2016, 18:00–19:20
Summit 2 Hall, Suntec Singapore
Convention & Exhibition Centre, Singapore
18:00 – 18:10
Welcome, introductions and opening presentation
18:10 – 18:35
Treatment choice in EGFR mutation-positive NSCLC
(presentation, case studies and panel discussion)
First-line irreversible ErbB family blockade
18:35 – 18:45
First-line treatment resistance: Mechanisms and treatment implications
18:45 – 18:55
Panel discussion: discussing the evidence
Panel led by Ross Soo
18:55 – 19:15
ErbB family blockade in advanced squamous cell carcinoma (SCC): Clinical insights (presentation, case studies and panel discussion)
19:15 – 19:20
Final questions, summary and meeting close